Participants were randomised to receive 50 ml of sterile sodium HA 1.6% and CS 2.0% solution (IALURIL) weekly for 4 week and then monthly for 5 months and evaluated addressing UTI status, urinary symptoms and general health related QoL questionnaire at baseline and after 3, 6, 9 and 12 months. Primary endpoint was defined as the mean number of UTI rate per patient/year.
Primary endpoint was defined as the mean rate of UTI episodes per patient/year.
Secondary outcome efficacy measures were time to UTI recurrence (defined as the time elapsed between the first instillation and the first recurring infection), variation in void frequency and volume, impact of therapy on QoL and rate of adverse events.
Copyright © 